CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 29 enrolled
Drug / intervention
Drug Cocktail +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03718884
NCT03718884Phase 1Completed
CompareCT.gov

Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis

Eli Lilly and Company·interventional·Posted Oct 25, 2018·Updated Jan 29, 2024

In Brief

A Phase 1 clinical trial evaluating Drug Cocktail and Mirikizumab for Psoriasis. Completed, enrolled 29 participants across 3 sites.

Detailed Summary

This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab. The study will last about 23 weeks for each participant. Screening must be completed within 4 weeks prior to study start.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedOct 25, 2018
Enrollment StartOct 23, 2018
Primary CompletionOct 28, 2019
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.7 years ago

Interventions

Drug Cocktaildrug

Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally

Mirikizumabdrug

Administered SC